Helius Medical Technologies, Inc. (HSDT) Income Statement
HSDT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsHSDT revenue and net income
Where HSDT's revenue goes
2025Each bar shows an amount and its share of revenue. HSDT kept −679.6% of revenue as net income.
HSDT profit margins
HSDT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +1,057.1% | +97.0% | +55.5% | — |
| Gross profit | — | +157.3% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
HSDT quarterly EPS vs estimates
Helius Medical Technologies beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 17, 2026 (estimate $0.02).
HSDT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.0M | $520,000 | $644,000 | $787,000 | $522,000 | $661,000 | $1.5M | $478,000 | $0 | $0 |
| Cost of revenue | $500,000 | $582,000 | $583,000 | $463,000 | $298,000 | $751,000 | $910,000 | $59,000 | $17,000 | $0 |
| Gross profit | $5.5M | −$62,000 | $61,000 | $324,000 | $224,000 | −$90,000 | $586,000 | $419,000 | −$17,000 | $0 |
| Research & development | $3.5M | $3.7M | $2.9M | $4.3M | $6.0M | $4.6M | $8.1M | $9.9M | $14.4M | $3.6M |
| Sales, general & admin | $23.1M | $10.1M | $9.6M | $10.6M | $12.2M | $9.7M | $16.5M | $17.2M | $8.5M | $5.7M |
| Total operating expenses | $26.6M | $13.8M | $12.5M | $15.8M | $18.4M | $14.0M | $24.6M | $27.1M | $22.8M | $9.3M |
| Operating income | −$21.1M | −$13.9M | −$12.4M | −$15.5M | −$18.1M | −$14.1M | −$24.0M | −$26.7M | −$22.9M | −$9.3M |
| Interest income | — | — | — | — | — | — | $14.1M | $2.0M | $0 | $111,000 |
| Interest expense | $635,000 | $17,000 | $257,000 | $834,000 | $10,000 | $256,000 | $14.2M | $1.9M | $5.2M | $46,920 |
| Income before taxes | −$40.9M | −$11.7M | −$8.8M | −$14.1M | −$18.1M | −$14.1M | −$9.8M | −$28.6M | −$28.0M | −$6.9M |
| Income taxes | — | — | −$5,895 | −$1.5M | −$10,000 | −$193,000 | −$14.1M | $4.0M | $10.3M | $1.7M |
| Net income | −$40.9M | −$11.7M | −$8.8M | −$14.1M | −$18.1M | −$14.1M | −$9.8M | −$28.6M | −$28.0M | −$6.9M |
| EBITDA | −$39.6M | −$13.8M | −$12.1M | −$14.5M | −$17.8M | −$13.6M | −$9.6M | −$28.6M | −$28.0M | −$6.8M |
| EPS (diluted) | −$1.85 | −$3560.51 | −$9120.34 | −$40876.30 | −$221251.54 | −$276375.22 | −$485625.24 | −$1249382.55 | −$13.41 | −$525621.51 |
| Gross margin | 91.7% | −11.9% | 9.5% | 41.2% | 42.9% | −13.6% | 39.2% | 87.7% | — | — |
| Operating margin | −351.0% | −2,673.7% | −1,929.8% | −1,971.5% | −3,475.5% | −2,129.5% | −1,604.0% | −5,580.5% | — | — |
| Net margin | −679.6% | −2,258.1% | −1,374.2% | −1,788.1% | −3,473.6% | −2,137.7% | −653.8% | −5,988.1% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $3.6M | $5.2M | $697,000 | $43,000 | $49,000 | $152,000 | $51,000 | $182,000 | $135,000 | $134,000 | $143,000 |
| Cost of revenue | $77,000 | $180,000 | $180,000 | $103,000 | $96,000 | $121,000 | $154,000 | $187,000 | $118,000 | $123,000 | $90,000 | $187,000 |
| Gross profit | $2.4M | $3.4M | $5.0M | $594,000 | −$53,000 | −$72,000 | −$2,000 | −$136,000 | $64,000 | $12,000 | $44,000 | −$44,000 |
| Research & development | — | — | $886,000 | $858,000 | $822,000 | $945,000 | $924,000 | $1.1M | $870,000 | $788,000 | $650,000 | $722,000 |
| Sales, general & admin | $11.1M | $5.2M | $13.0M | $4.6M | $2.4M | $3.0M | $2.2M | $2.9M | $2.5M | $2.6M | $1.6M | $2.2M |
| Total operating expenses | $11.1M | $5.2M | $13.9M | $5.5M | $3.3M | $3.9M | $3.1M | $3.9M | $3.3M | $3.4M | $2.3M | $3.1M |
| Operating income | −$8.7M | −$1.7M | −$8.9M | −$4.9M | −$3.3M | −$4.0M | −$3.1M | −$4.1M | −$3.3M | −$3.4M | −$2.2M | −$3.2M |
| Interest expense | $67,000 | — | $1.3M | $1,000 | $628,000 | $6,000 | $3,000 | $1,000 | $5,000 | $8,000 | $68,000 | — |
| Income before taxes | −$30.3M | −$99.8M | $325.6M | −$352.8M | −$9.8M | −$3.8M | −$3.9M | −$3.7M | −$1.6M | −$2.5M | −$1.0M | −$3.7M |
| Income taxes | — | — | — | — | — | — | — | — | −$16,000 | −$27,276 | −$1 | $676,000 |
| Net income | −$30.3M | −$99.8M | $325.6M | −$352.8M | −$9.8M | −$3.8M | −$3.9M | −$3.7M | −$1.6M | −$2.5M | −$1.0M | −$3.7M |
| EBITDA | −$8.7M | −$99.8M | $325.6M | −$352.1M | −$9.2M | −$3.8M | −$3.1M | −$3.7M | −$1.6M | −$2.5M | −$1.0M | −$2.9M |
| EPS (diluted) | −$0.05 | −$1.30 | — | −$32.89 | −$79.73 | −$391.72 | −$1.01 | −$769.50 | −$480.00 | −$2310.00 | −$1.47 | −$3493.87 |
| Gross margin | 97.0% | 95.0% | 96.6% | 85.2% | −123.3% | −146.9% | −1.3% | −266.7% | 35.2% | 8.9% | 32.8% | −30.8% |
| Operating margin | −343.1% | −48.3% | −169.8% | −704.4% | −7,725.6% | −8,185.7% | −2,070.4% | −7,980.4% | −1,796.7% | −2,530.4% | −1,676.1% | −2,204.9% |
| Net margin | −1,197.8% | −2,756.1% | 6,227.1% | −50,612.3% | −22,867.4% | −7,832.7% | −2,584.2% | −7,227.5% | −885.7% | −1,863.7% | −779.9% | −2,561.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in HSDT's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
HSDT financial results
In fiscal year 2025 (ended December 31, 2025), Helius Medical Technologies reported revenue of $6.0 million, up 1,057.1% from the year before. It had a net loss of $40.9 million, a net profit margin of −679.6%. Diluted earnings per share came to −$1.85. Over five years revenue grew at an average rate of 55.5% a year.
See the HSDT stock overview for the latest quote and news, or the HSDT chart for price history and technical indicators.
HSDT income statement FAQ
What is Helius Medical Technologies's annual revenue?
Helius Medical Technologies reported total revenue of $6.0 million for fiscal year 2025, which ended on December 31, 2025. That was up 1,057.1% from $0.5 million the previous year.
Is Helius Medical Technologies profitable?
No. Helius Medical Technologies reported a net loss of $40.9 million in fiscal 2025, a net profit margin of −679.6%; its operating margin was −351.0%.
What is Helius Medical Technologies's gross margin?
Helius Medical Technologies's gross margin was 91.7% in fiscal 2025: for every $100 of revenue, Helius Medical Technologies kept $92 after the direct cost of its products and services.
How much does Helius Medical Technologies spend on research and development?
Helius Medical Technologies spent $3.5 million on research and development in fiscal 2025, 58.4% of revenue.
How fast is Helius Medical Technologies growing?
Revenue grew 55.5% a year on average over the last five fiscal years, from $0.7 million to $6.0 million.
What are Helius Medical Technologies's earnings per share?
Helius Medical Technologies earned $-1.85 per diluted share in fiscal 2025, compared with $-3560.51 a year earlier.
When will Helius Medical Technologies report its next earnings?
Helius Medical Technologies is expected to report results for the quarter ending September 30, 2026 on November 17, 2026.
When does Helius Medical Technologies's fiscal year end?
Helius Medical Technologies's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.